Diabetes: a time for excitement---and concern

BMJ 1998;317:691-692 ( 12 September )

Editorials

Diabetes: a time for excitement $---$ and concern

Hopeful signs exist that the ravages of diabetes can be tamed

Editorial p 693 Papers pp 703 , 713 , 720

The first 150 words of the full text of this article appear below.

These are exciting, and exasperating, times for people interested in diabetes. On the one hand, a tremendous volume of researchis underway assessing both new prevention and new treatment protocols;on the other, the incidence (and associated mortality and morbidity)of this disease continues to rise with little sign of abating.Indeed, by 2010 the world's diabetic population will probablyhave doubled from an estimated 110 million in 1994 to 221 millionin 2010.¹ What have we learnt recently about the epidemiology,causation, and prevention of this condition?

Prevalence varies widely by ethnic group and country (adult rates range from <2% in rural Bantu people in Tanzania to nearly50% in US Pima Indians and South Pacific Naurauns¹). Ratesare also relatively high in "transplanted populations," such asAsians in Europe² and African Americans.³ The projectedincrease in rates, however, is universal. Though this rise ismainly due to type 2 diabetes, alarming increases . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Articles

Diabetes and death
BMJ 1998 317: 0. [Full Text]

Good news on diabetes, bad news on nose drops
BMJ 1998 317: 0. [Full Text]

Combined high blood pressure and glucose in type 2 diabetes: double jeopardy: Carl Erik Mogensen
BMJ 1998 317: 693-694. [Extract] [Full Text] [PDF]

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group
BMJ 1998 317: 703-713. [Abstract] [Full Text] [PDF]

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39: UK Prospective Diabetes Study Group
BMJ 1998 317: 713-720. [Abstract] [Full Text] [PDF]

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40: UK Prospective Diabetes Study Group
BMJ 1998 317: 720-726. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

Stephens, J. W, Humphries, S. E, Cooper, J. A, Hurel, S. J (2004). What are the clinical manifestations of cardiovascular disease in diabetes? Ten year analysis from a clinic based population. British Journal of Diabetes & Vascular Disease 4: 190-194 [Abstract]
Samuel, T., Cockwell, P. (2002). Islet cell transplantation. JRSM 95: 31-33 [Full text]
Krentz, A. J, Bailey, C. J, Melander, A. (2000). Thiazolidinediones for type 2 diabetes. BMJ 321: 252-253 [Full text]
Orchard, T. J. (1999). Magnesium and Type 2 Diabetes Mellitus. Arch Intern Med 159: 2119-2120 [Full text]